Literature DB >> 20654461

Characterization of cytochrome P450 isoenzymes in primary cultures of pig hepatocytes.

M Monshouwer1, G A Van't Klooster, S M Nijmeijer, R F Witkamp, A S van Miert.   

Abstract

Despite the fact that pigs are increasingly used in pharmacological and toxicological studies, knowledge on the enzymes which metabolize xenobiotics, in particular cytochrome P450 (CYP) enzymes, in pigs is still very limited. Primary cultures of pig hepatocytes were used to characterize CYP enzymes. The characterization was performed at the level of enzymatic activities, apoprotein and mRNA analyses. Enzyme inducers investigated were beta-naphthoflavone (BNF), phenobarbital (PB), dexamethasone (DEX) and rifampicin (RIF). After 48hr of BNF treatment, CYP1A protein and mRNA levels were increased, and ethoxyresorufin O-deethylation and caffeine 3-demethylation were strongly induced. PB and RIF increased the levels of CYP3A apoprotein and mRNA, whereas BNF down-regulated CYP3A and related activities. PB and RIF treatment resulted in increased ethylmorphine N-demethylation and testosterone hydroxylation, which appears to be the result of CYP3A induction. Hybridization of pig RNA with a human CYP2C9 cDNA probe showed a PB and RIF inducible CYP, which was down-regulated by BNF. Similar inducing effects were observed for tolbutamide, a marker substrate for CYP2C. DEX was not a potent inducer, although some induction of CYP3A mRNA was observed. The present results indicate the absence of CYP2B and probably CYP2D enzymes and activities in pig liver. Despite some dissimilarities, the results indicate that pigs, apart from their very human-like physiology, might represent a more appropriate model species for oxidative drug metabolism in humans than rats.

Entities:  

Year:  1998        PMID: 20654461     DOI: 10.1016/s0887-2333(98)00053-8

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  8 in total

1.  Minipig cytochrome P450 3A, 2A and 2C enzymes have similar properties to human analogs.

Authors:  P Soucek; R Zuber; E Anzenbacherová; P Anzenbacher; F P Guengerich
Journal:  BMC Pharmacol       Date:  2001-12-05

Review 2.  Regulation of porcine hepatic cytochrome p450 - implication for boar taint.

Authors:  Martin Krøyer Rasmussen; Galia Zamaratskaia
Journal:  Comput Struct Biotechnol J       Date:  2014-09-10       Impact factor: 7.271

3.  Establishment and long-term maintenance of primary intestinal epithelial cells cultured from the rainbow trout, Oncorhynchus mykiss.

Authors:  Laura M Langan; Stewart F Owen; Awadhesh N Jha
Journal:  Biol Open       Date:  2018-03-07       Impact factor: 2.422

4.  Potential Pharmacokinetic Drug⁻Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist.

Authors:  Yunpeng Zhang; Shuping Li; Youxu Wang; Gang Deng; Ning Cao; Chao Wu; Wenzheng Ding; Yuwen Wang; Xuemei Cheng; Changhong Wang
Journal:  Molecules       Date:  2019-04-11       Impact factor: 4.411

Review 5.  Alcohol Induced Brain and Liver Damage: Advantages of a Porcine Alcohol Use Disorder Model.

Authors:  Soo K Shin; Erin E Kaiser; Franklin D West
Journal:  Front Physiol       Date:  2021-01-07       Impact factor: 4.566

6.  EROD and MROD as Markers of Cytochrome P450 1A Activities in Hepatic Microsomes from Entire and Castrated Male Pigs.

Authors:  Galia Zamaratskaia; Vladimir Zlabek
Journal:  Sensors (Basel)       Date:  2009-03-23       Impact factor: 3.576

7.  Profiling the impact of medium formulation on morphology and functionality of primary hepatocytes in vitro.

Authors:  Leonard J Nelson; Philipp Treskes; A Forbes Howie; Simon W Walker; Peter C Hayes; John N Plevris
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

8.  Cecropin B Represses CYP3A29 Expression through Activation of the TLR2/4-NF-κB/PXR Signaling Pathway.

Authors:  Xiaoqiao Zhou; Xiaowen Li; Xiliang Wang; Xiue Jin; Deshi Shi; Jun Wang; Dingren Bi
Journal:  Sci Rep       Date:  2016-06-14       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.